We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

2 hedge funds and large institutions have $35.8K invested in Eagle Pharmaceuticals, Inc. in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

196% more capital invested

Capital invested by funds: $12.1K → $35.8K (+$23.7K)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SLG
1
Stanley-Laman Group
Pennsylvania
$34.8K – – –
AIC
2
Archer Investment Corporation
Indiana
$1.01K – – –

EGRX Hedge Fund Activity: Q2 2025 in Review

2 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2025, worth a combined $35.8K — up 196% from $12.1K a quarter earlier.

Fund positioning in EGRX was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $35.8K of Eagle Pharmaceuticals, Inc. stock for Q2 2025, up 196% quarter-over-quarter.
  • 0 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2025 and 0 closed out.

Based on aggregated 13F filings for Q2 2025.